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A commentary on
Neuropsychological assessment of individuals with brain tumor: comparison of approaches
used in the classification of impairment
by Dwan TM, Ownsworth T, Chambers S, Walker DG, Shum DHK. Front Oncol (2015) 5:56. doi:
10.3389/fonc.2015.00056
Neurocognitive functioning (NCF) has been increasingly recognized as an important contributor to
quality of life in patients with cerebral neoplasms. Accordingly, studies of NCF in this population
have grown tremendously over the past few decades, and performance-based neuropsychological
measures assessing diverse NCF domains are now routinely included in brain tumor clinical trials
(1). However, little consensus exists regarding the prevalence of NCF impairment in this population,
with Dwan et al. noting that rates reported in the literature vary from around 13% to over 90%
(2). Numerous factors contribute to the widely differing impairment rates across studies, including
tumor characteristics (histology, lesion size, and location) (3), patient demographics (socioeconomic
status and age) (4), and treatments received (surgical resection and/or chemoradiation) (5).
The article by Dwan and colleagues highlights method variance as another important contributor
to the variability in rates of NCF impairment reported. The authors adeptly point to a substantial
lack of consistency in impairment classification schemas throughout the literature. Utilizing a few
of the more commonly employed classification strategies in a sample of patients with brain tumors,
they also demonstrate that classification of impairment based upon intra-individual comparison
to estimated premorbid intellectual function differs from classification using published norms or
matched controls. The authors then conclude that “this supports the need to interpret individuals’
neuropsychological test results in the context of their estimated premorbid IQ.” While we agree
with Dwan et al. that consideration of premorbid functioning is important when interpreting
neuropsychological test results, we believe that the approach utilized in their report may be prone to
misclassification for reasons discussed below, and we briefly suggest an alternative that is potentially
more statistically sound and robust.
In the analyses under discussion, the authors classify a test score as “impaired” if it falls at least one
SD below the patient’s own premorbid intellectual function estimate, as determined by performance
on a word-reading task. This method is economical and demands minimal statistical sophistication,
making it attractive for use in clinical and research settings alike. However, as the authors briefly
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acknowledge, the approach risks elevating false positive (Type
I) error rates for individuals at the upper tail of the premorbid
intellectual distribution, as well as false negative errors (Type
II) for those at the lower end of the distribution. Importantly,
risk of error tends to increase with the number of tests included
in a battery, which are numerous in routine neuropsychological
practice, and when comparisons are made at the individual test
level rather than domain level. A related issue involves differences
between correlations among tests. Since tests of NCF vary in sen-
sitivity, ceiling/floor levels, and domains of specificity, uniform
correlations between measures of premorbid intellectual function
and other tests are unlikely. This is problematic since it cannot
be assumed that low-average estimated premorbid intellectual
function entails that visual memory, processing speed, executive
function, and performances within other domains should also be
low average.
Fortunately, various methods exist to address aspects of these
concerns. While a comprehensive delineation of the numerous
techniques is beyond the scope of this paper, one popular method
involves calculation of regression-based norms from healthy con-
trol data (6). With this approach, various variables can be used
to build equations predicting expected performances for each test
from estimates of premorbid intellectual function, age, education,
and other factors known to influence NCF. With this method, the
predicted (or expected) score can then be directly compared to the
observed performance for an individual patient using inferential
statistical analyses.
While this method has its own limitations and is by no means
the only viable alternative, it has been shown to improve test sen-
sitivity (6). Additionally, simulation studies show that variations
of the technique have low classification error rates, even when
control samples are relatively small (7). Some may object that
these analyses are complicated and impractical. However, user
friendly and freely available computer programs exist to facilitate
the use of such methods (8, 9). These approaches can even be
employed in studies lacking a healthy control group by substi-
tuting summary data gleaned from test manuals or previously
published reports. Accordingly, consideration of including these
and other novel analytical techniques into future studies regard-
ing classification methodology is warranted, which may facilitate
more precise prevalence estimates ofNCF in patientswith cerebral
tumors.
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